Abstract
We present here a discussion on the most relevant recent publications on mitochondrial disease. In addition to many papers concerning the description of the genotype-to-phenotype correlations in mitochondrial DNA-related disorders, this very broad area of neurogenetics includes a number of novel observations on the basic aspects of mitochondrial biogenesis that can be relevant in explaining the molecular mechanisms of mitochondrial abnormalities. The completion of the human genome project and the wealth of knowledge gained on the genetics of oxidative phosphorylation in yeast have promoted a substantial acceleration in the discovery of a remarkable number of nuclear genes associated with specific mitochondrial disorders. A further development of these contributions has been the generation of several cellular and animal models of disease that can now be exploited for testing both pathogenetic hypotheses and therapeutic strategies. Most of the latter are based on the use of chemical compounds aimed at reducing the negative impact of mitochondrial defects on both energy production and generation of reactive oxygen species. The first successful attempts for gene therapy of some mitochondrial diseases have recently been achieved and will hopefully increase in the near future.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Shanske S, Tang Y, Hirano M, et al.: Identical mitochondrial DNA deletion in a woman with ocular myopathy and in her son with pearson syndrome. Am J Hum Genet 2002, 71:679–683. This work demonstrates that although the vast majority of single, large-scale deletions in mtDNA are sporadic, in rare cases single deletions can be transmitted through the germline.
Schwartz M and Vissing J: Paternal inheritance of mtDNA. N Engl J Med 2002, 347:576–580.
Battersby BJ, Loredo-Osti JC, Shoubridge EA: Nuclear genetic control of mitochondrial DNA segregation. Nat Genet 2003, 33:183–186. This is the first genetic evidence for nuclear control of mammalian mtDNA segregation. This finding can have important consequences on the therapeutic attempts to control the mutation load of pathogenic heteroplasmic mutations leading to OXPHOS failure in humans.
Yang MY, Bowmaker M, Reyes A, et al.: Biased incorporation of ribonucleotides on the mitochondrial L-strand accounts for apparent strand-asymmetric DNA replication. Cell 2002, 111:495–505. This article concludes that mammalian mtDNA replication may well proceed mainly, or exclusively, by a strand-coupled mechanism.
Falkenberg M, Gaspari M, Rantanen A, et al.: Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. Nat Genet 2002, 31:289–294. The presence of two proteins that interact with mammalian POLRMT may allow flexible regulation of mtDNA gene expression in response to the complex physiologic demands of mammalian metabolism.
Crimi M, Sciacco M, Galbiati S, et al.: A collection of 33 novel human mtDNA homoplasmic variants. Hum Mutat 2002, 20:409–0.
He L, Chinnery PF, Durham SE, et al.: Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res 2002, 30:e68.
Choo-Kang AT, Lynn S, Taylor GA, et al.: Defining the importance of mitochondrial gene defects in maternally inherited diabetes by sequencing the entire mitochondrial genome. Diabetes 2002, 51:2317–20.
Corona P, Lamantea E, Greco M, et al.: Novel heteroplasmic mtDNA mutation in a family with heterogeneous clinical presentations. Ann Neurol 2002, 51:118–122.
Lamantea E, Carrara F, Mariotti C, et al.: A novel nonsense mutation (Q352X) in the mitochondrial cytochrome b gene associated with a combined deficiency of complexes I and III. Neuromuscul Disord 2002, 12:49–52.
Taylor RW, Schaefer AM, McFarland R, et al.: A novel mitochondrial DNA tRNA(Ile) (A4267G) mutation in a sporadic patient with mitochondrial myopathy. Neuromuscul Disord 2002, 12:659–664.
Sacconi S, Salviati L, Sue CM, et al.: Mutation screening in patients with isolated cytochrome c oxidase deficiency. Pediatr Res 2003, 53:224–230.
Valentino ML, Avoni P, Barboni P, et al.: Mitochondrial DNA nucleotide changes C14482G and C14482A in the ND6 gene are pathogenic for Leber’s hereditary optic neuropathy. Ann Neurol 2002, 51:774–778. There are seven mutations in the ND6 gene leading to LHON. All of them lie within the most evolutionarily conserved region of the ND6 gene, making it a hot spot for the disease.
McFarland R, Clark KM, Morris AA, et al.: Multiple neonatal deaths due to a homoplasmic mitochondrial DNA mutation. Nat Genet 2002, 30:145–146. This study highlights the role of homoplasmic mt-tRNA mutations in genetic disease. The surprising finding here is not the multiple affected siblings generated by the mutant mother, but her virtual absence of clinical symptoms.
Funalot B, Reynier P, Vighetto A, et al.: Leigh-like encephalopathy complicating Leber’s hereditary optic neuropathy. Ann Neurol 2002, 52:374–377.
Taylor RW, Morris AA, Hutchinson M, et al.: Leigh disease associated with a novel mitochondrial DNA ND5 mutation. Eur J Hum Genet 2002, 10:141–144.
Horvath R, Scharfe C, Hoeltzenbein M, et al.: Childhood onset mitochondrial myopathy and lactic acidosis caused by a stop mutation in the mitochondrial cytochrome c oxidase III gene. J Med Genet 2002, 39:812–816.
Chol M, Lebon S, Benit P, et al.: The mitochondrial DNA G13513A MELAS mutation in the NADH dehydrogenase 5 gene is a frequent cause of Leigh-like syndrome with isolated complex I deficiency. J Med Genet 2003, 40:188–191. It appears that this mutation represents a frequent cause of Leigh-like syndrome. It should be systematically tested for by molecular diagnosis in affected children and their maternal relatives should receive genetic counseling.
Zhang J, Asin-Cayuela J, Fish J, et al.: Strikingly higher frequency in centenarians and twins of mtDNA mutation causing remodeling of replication origin in leukocytes. Proc Natl Acad Sci U S A 2003, 100:1116–1121.
Wang Y, Michikawa Y, Mallidis C, et al.: Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. Proc Natl Acad Sci U S A 2001, 98:4022–4027.
Fayet G, Jansson M, Sternberg D, et al.: Ageing muscle: clonal expansions of mitochondrial DNA point mutations and deletions cause focal impairment of mitochondrial function. Neuromusc Disord 2002, 12:484–493.
Chinnery PF, Samuels DC, Elson J, Turnbull DM: Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism? Lancet 2002, 360:1323–1325.
Suzuki T, Suzuki T, Wada T, et al.: Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases. EMBO J 2002, 21:6581–6589. This is the first reported evidence that taurine is a constituent of biologic macromolecules, unveiling the prospect of obtaining new insights into the functions and subcellular localization of this abundant amino acid.
Feuermann M, Francisci S, Rinaldi T, et al.: The yeast counterparts of human ‘MELAS’ mutations cause mitochondrial dysfunction that can be rescued by overexpression of the mitochondrial translation factor EF-Tu. EMBO Rep 2003, 4:53–58. This study supports the possibility of using yeast as a means to validate the pathogenicity of human tRNA mutations in vivo.
Qi X, Lewin AS, Hauswirth WW, Guy J: Suppression of complex I gene expression induces optic neuropathy. Ann Neurol 2003, 53:198–205. The ribozyme-induced suppression of a nuclear-encoded subunit gene of complex I (NDUFA1) led to axonal destruction and demyelination, which are the hallmarks of LHON.
Qi X, Lewin AS, Hauswirth WW, Guy J: Optic neuropathy induced by reductions in mitochondrial superoxide dismutase. Invest Ophthalmol Vis Sci 2003, 44:1088–1096. The striking similarity of the optic neuropathy to the histopathology of LHON is powerful evidence supporting reactive oxygen species as a key factor in the pathogenesis of LHON.
Wredenberg A, Wibom R, Wilhelmsson H, et al.: Increased mitochondrial mass in mitochondrial myopathy mice. Proc Natl Acad Sci U S A 2002, 99:15066–15071. Biochemical measurements of ATP-production rate and in vitro physiologic studies suggest that reduced mitochondrial ATP production might not be as critical for the pathophysiology of mitochondrial myopathy as thought previously.
Man PY, Griffiths PG, Brown DT, et al.: The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet 2003, 72:333–339. A total of 16 genealogically unrelated families harbored one of the three primary mtDNA mutations that cause LHON. Two of these families were linked genetically to a common maternal founder. A de novo mtDNA mutation was identified in one family. The minimum point prevalence of visual failure due to LHON within this population was 3.22 per 100,000 and the minimum point prevalence for mtDNA LHON mutations was 11.82 per 100,000.
Taivassalo T, Jensen TD, Kennaway N, et al.: The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 2003, 126:413–423. In the MM patients, mean peak-work capacity and oxygen uptake were significantly lower than in control subjects, but the patient range was broad. Oxidative capacity in patients was limited by the ability of muscle to extract available oxygen from blood Likewise, the increase in cardiac output relative to volume of oxygen consumption and ventilation were exaggerated compared with control subjects.
Wolf NI, Smeitink JA: Mitochondrial disorders: a proposal for consensus diagnostic criteria in infants and children. Neurology 2002, 59:1402–1405. These results suggested that the proposed Mitochondrial Disease Criteria classification allow more precise definition of clinical and metabolic items and the independent scoring of muscle biochemical investigations before combining all findings to determine the overall diagnostic certainty.
Janssen R, Smeitink J, Smeets R, van Den Heuvel L: CIA30 complex I assembly factor: a candidate for human complex I deficiency? Hum Genet 2002, 110:264–270.
Rustin P, Rotig A: Inborn errors of complex II—unusual human mitochondrial diseases. Biochim Biophys Acta 2002, 1553:117–122.
Maher ER, Eng C: The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 2002, 11:2347–2354.
Neumann HP, Bausch B, McWhinney SR, et al.: Germ-line mutations in nonsyndromic phaeochromocytoma. N Engl J Med 2002, 346:1459–1466.
Gimenez-Roqueplo AP, Favier J, Rustin P, et al.: Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 2002, 87:4771–4774.
Tomlinson IP, Alam NA, Rowan AJ, et al.: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30:406–410. The gene acts as a typical tumor suppressor, with loss of the functional allele occurring in benign smooth muscle tumors and renal cell cancer. This finding is of obvious importance in view of the high incidence and associated morbidity of uterine fibroids, which account for nearly 25% of all healthcare-related expenditure in Western gynecology clinical practices.
Van Maldergem L, Trijbels F, DiMauro S, et al.: Coenzyme Q-responsive Leigh’s encephalopathy in two sisters. Ann Neurol 2002, 52:750–754.
Barrientos A, Korr D, Tzagoloff A: Shy1p is necessary for full expression of mitochondrial COX1 in the yeast model of Leigh’s syndrome. EMBO J 2002, 21:43–52.
Agostino A, Invernizzi F, Tiveron C, et al.: Constitutive knockout of Surf1 is associated with high embryonic lethality, mitochondrial disease and cytochrome c oxidase deficiency in mice. Hum Mol Genet 2003, 12:399–413. This is the first mammalian knockout model for a nuclear gene responsible for a mitochondrial disease in humans. These results indicate a function for murine Surf1 protein specifically related to COX and recapitulate, at least in part, the human phenotype.
Salviati L, Sacconi S, Rasalan MM, et al.: Cytochrome c oxidase deficiency due to a novel SCO2 mutation mimics Werdnig-Hoffmann disease. Arch Neurol 2002, 59:862–865.
Salviati L, Hernandez-Rosa E, Walker WF, et al.: Copper supplementation restores cytochrome c oxidase activity in cultured cells from patients with SCO2 mutations. Biochem J 2002, 363:321–327. This paper reports that COX deficiency observed in fibroblasts, myoblasts and myotubes from patients with SCO2 mutations can be restored to almost normal levels by the addition of copper chloride to the growth medium. This result suggests a possible therapy for the early treatment of this fatal infantile disease by increasing the intracellular content of copper in critical tissues.
Takahashi Y, Kako K, Kashiwabara S, et al.: Mammalian copper chaperone Cox17p has an essential role in activation of cytochrome c oxidase and embryonic development. Mol Cell Biol 2002, 22:7614–7622.
Antonicka H, Mattman A, Carlson CG, et al.: Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. Am J Hum Genet 2003, 72:101–114. This study establishes COX15 as an additional cause, along with SCO2, of fatal infantile hypertrophic cardiomyopathy associated with isolated COX deficiency.
Visapaa I, Fellman V, Vesa J, et al.: GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. Am J Hum Genet 2002, 71:863–876. A defect in complex III was found in several, but not in all, of the GRACILE patients examined in this study, suggesting that BCS1L may have an additional cellular function, possibly involved in iron metabolism. This controversial hypothesis remains to be proven.
Lamantea E, Tiranti V, Bordoni A, et al.: Mutations of mitochondrial DNA polymerase A are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol 2002, 52:211–219. According to this study, carried out on the largest cohort of familial PEO available in the world, POLG1 mutations account for approximately 45%, Twinkle mutations for 36%, and ANT1 mutations for 7% of the cases.
Van Goethem G, Martin JJ, Dermaut B, et al.: Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 2003, 13:133–142.
Agostino A, Valletta L, Chinnery PF, et al.: Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology 2003, 60:1354–1356.
Ponamarev MV, Longley MJ, Nguyen D, et al.: Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis. J Biol Chem 2002, 277:15225–15228. This study suggests that mutant DNA polymerase gamma could determine error-prone mtDNA synthesis in vivo and produce accumulation of mtDNA mutations in patients with PEO.
Mancuso M, Salviati L, Sacconi S, et al.: Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology 2002, 59:1197–1202.
Salviati L, Sacconi S, Mancuso M, et al.: Mitochondrial DNA depletion and dGK gene mutations. Ann Neurol 2002, 52:311–317.
Spinazzola A, Marti R, Nishino I, et al.: Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002, 277:4128–4133. The authors of this paper hypothesize that excess thymidine alters mitochondrial nucleoside and nucleotide pools, leading to impaired mitochondrial DNA replication, repair, or both. An important corollary to this study is that, in principle, therapies to reduce thymidine levels may be beneficial to MNGIE patients.
Haraguchi M, Tsujimoto H, Fukushima M, et al.: Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. Mol Cell Biol 2002, 22:5212–5221. In contrast with human patients, these mice did not show alterations of mitochondrial DNA or pathologic changes in muscle, although, like in MNGIE, thymidine levels were substantially increased. However, hyperintense lesions were detected on magnetic resonance T2 maps in the brain and axonal edema by electron microscopic study of the brain in thymidine phosphorylase-null and uridine phosphorylase-null mice.
Rosenberg MJ, Agarwala R, Bouffard G, et al.: Mutant deoxynucleotide carrier is associated with congenital microcephaly. Nat Genet 2002, 32:175–179. These data indicate that mitochondrial deoxynucleotide transport may be essential for fetal brain development. Further investigation will verify whether, as for other conditions due to altered deoxynucleotide metabolism in mitochondria, the central mechanism underlying MHCPA can be a severe, prenatal depletion and/or disruption of mtDNA.
Kelley RI, Robinson D, Puffenberger EG, et al.: Amish lethal microcephaly: a new metabolic disorder with severe congenital microcephaly and 2-ketoglutaric aciduria. Am J Med Genet 2002, 112:318–326. Further investigation will verify whether, as for other conditions due to altered deoxynucleotide metabolism in mitochondria, the central mechanism underlying MHCPA can be a severe, prenatal depletion and/or disruption of mtDNA.
Schlame M, Towbin JA, Heerdt PM, et al.: Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann Neurol 2002, 51:634–637.
Valianpour F, Wanders RJ, Overmars H, et al.: Cardiolipin deficiency in X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM 302060): a study in cultured skin fibroblasts. J Pediatr 2002, 141:729–733.
De Lonlay P, Mugnier C, Sanlaville D, et al.: Cell complementation using Genebridge 4 human:rodent hybrids for physical mapping of novel mitochondrial respiratory chain deficiency genes. Hum Mol Genet 2002, 11:3273–3281. This article discusses an approach that makes the physical mapping of the disease genes feasible in sporadic cases of OXPHOS deficiency.
Steinmetz LM, Scharfe C, Deutschbauer AM, et al.: Systematic screen for human disease genes in yeast. Nat Genet 2002, 31:400–404.
Mootha VK, Lepage P, Miller K, et al.: Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci USA 2003, 100:605–610. By intersecting information derived from RNA expression data sets and a large survey of organellar proteomics with the relevant genomic region, a single, clear candidate gene was identified and then proven to be mutated in affected individuals.
Komura K, Hobbiebrunken E, Wilichowski EK, Hanefeld FA:Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol 2003, 28:53–58.
Hausse AO, Aggoun Y, Bonnet D, et al.: Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart 2002, 87:346–349.
Artuch R, Aracil A, Mas A, et al.: Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics 2002, 33:190–193.
Manfredi G, Fu J, Ojaimi J, et al.: Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNAencoded gene, to the nucleus. Nat Genet 2002, 30:394–399.
Guy J, Qi X, Pallotti F, et al.: Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol 2002, 52:529–530. A synthetic ND4 subunit compatible with the "universal" genetic code containing a mitochondrial leader peptide was expressed in cybrids harboring the G11778A mutation. The recombinant protein was able to enter the organelles and induce a threefold increase in ATP synthesis, which is a level indistinguishable from that in cybrids containing normal mitochondrial DNA.
Tanaka M, Borgeld HJ, Zhang J: Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci 2002, 9:534–541. The elimination of the mutant mtDNA species was followed by restoration of both the normal intracellular ATP level and normal mitochondrial membrane potential. Delivery of restriction enzymes into mitochondria is a novel strategy for gene therapy in selected cases of mitochondrial disease.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zeviani, M., Spinazzola, A. Mitochondrial disorders. Curr Neurol Neurosci Rep 3, 423–432 (2003). https://doi.org/10.1007/s11910-003-0026-9
Issue Date:
DOI: https://doi.org/10.1007/s11910-003-0026-9